For Parkinson’s patients, the drug that restores movement can stop working reliably and cause involuntary movements of its own. A new candidate from UC San Diego-born biotech Sinopia Biosciences may fix both — boosting L-dopa’s benefits while easing dyskinesia.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
